Melanoma Clinical Trials in New York

Showing 21-40 of 341 trials

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

NCT05289193

Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.

MelanomaMelanoma Stage III

Memorial Sloan Kettering Cancer Center28 participantsStarted Mar 2022

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Harrison, New York, United States +1 more locations

RECRUITINGPhase 1/2< 1 mile

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

Melanoma Stage IVSolid Tumor

Georgiamune Inc117 participantsStarted May 2024

Scottsdale, Arizona, United States • Bakersfield, California, United States • Fullerton, California, United States +8 more locations

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Melanoma Trials in Other Cities

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Dinaciclib in Treating Patients With Stage IV Melanoma

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Other Conditions in New York